Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Interest Expenses (2016 - 2020)

Historic Interest Expenses for Outlook Therapeutics (OTLK) over the last 6 years, with Q2 2020 value amounting to $443624.0.

  • Outlook Therapeutics' Interest Expenses fell 5899.13% to $443624.0 in Q2 2020 from the same period last year, while for Jun 2025 it was $443624.0, marking a year-over-year change of. This contributed to the annual value of $3.2 million for FY2024, which is 2472.06% up from last year.
  • Per Outlook Therapeutics' latest filing, its Interest Expenses stood at $443624.0 for Q2 2020, which was down 5899.13% from $696151.0 recorded in Q1 2020.
  • In the past 5 years, Outlook Therapeutics' Interest Expenses registered a high of $2.1 million during Q3 2017, and its lowest value of $210183.0 during Q3 2019.
  • In the last 5 years, Outlook Therapeutics' Interest Expenses had a median value of $819376.5 in 2017 and averaged $898558.3.
  • Per our database at Business Quant, Outlook Therapeutics' Interest Expenses skyrocketed by 48293.81% in 2017 and then plummeted by 8098.11% in 2019.
  • Over the past 5 years, Outlook Therapeutics' Interest Expenses (Quarter) stood at $489145.0 in 2016, then skyrocketed by 46.76% to $717883.0 in 2017, then soared by 56.13% to $1.1 million in 2018, then crashed by 46.68% to $597665.0 in 2019, then dropped by 25.77% to $443624.0 in 2020.
  • Its last three reported values are $443624.0 in Q2 2020, $696151.0 for Q1 2020, and $597665.0 during Q4 2019.